Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation (original) (raw)

2014, Pharmacoepidemiology and drug safety

Abstract

Abuse of opioid analgesics for their psychoactive effects is associated with a large number of fatalities. The effect of making opioid tablets harder to crush/dissolve on opioid-related fatalities has not been assessed. The objective of this study was to assess the impact of introducing extended-release oxycodone (ERO [OxyContin(®) ]) tablets containing physicochemical barriers to crushing/dissolving (reformulated ERO) on deaths reported to the manufacturer. All spontaneous adverse event reports of death in the US reported to the manufacturer between 3Q2009 and 3Q2013 involving ERO were used. The mean numbers of deaths/quarter in the 3 years after reformulated ERO introduction were compared with the year before. Changes in the slope of trends in deaths were assessed using spline regression. Comparison groups consisted of non-fatal reports involving ERO and fatality reports involving ER morphine. Reports of death decreased 82% (95% CI: -89, -73) from the year before to the third year...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (56)

  1. American Academy of Pain Medicine. Use of Opioids for the Treatment of Chronic Pain. American Academy of Pain Medicine: Chicago, IL, 2013.
  2. American Geriatrics Society Panel on Pharmacological Management of Persis- tent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57: 1331-1346. doi. 10.1111/j.1532- 5415.2009.02376.x.
  3. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130. doi:10.1016/j.jpain.2008.10.008.
  4. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Department of Veterans Affairs, Department of Defense: Washington, DC, 2010.
  5. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Part B: recommendations for practice. National Opioid Use Guideline Group (NOUGG): Hamilton, Canada, 2010.
  6. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309: 657-659. doi:10.1001/jama.2013.272.
  7. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1983. doi:10.1056/NEJMp1011512.
  8. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005; 11: 469-479.
  9. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006; 22: 667-676.
  10. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-1675. doi:10.2165/11537940-000000000-00000.
  11. Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alco- hol Abuse 2011; 37: 205-217. doi:10.3109/00952990.2011.569623.
  12. National Drug Intelligence Center. OxyContin diversion and abuse. January 2001. http://www.justice.gov/archive/ndic/pubs/651/abuse.htm [23 February 2012].
  13. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 2003; 1: 423-428.
  14. Hays LR. A profile of OxyContin addiction. J Addict Dis 2004; 23: 1-9.
  15. Butler SF, Black RA, Grimes Serrano JM, et al. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns and functional severity. J Opioid Manag 2010; 6: 239-252.
  16. Romach MB, Schoedel KA, Seller EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend 2013; 130: 13-23. doi:10.1016/j. drugalcdep.2012.12.028.
  17. Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opi- oids for chronic nonmalignant pain. PT 2012; 37: 412-418.
  18. OxyContin [full prescribing information].
  19. Stamford, CT: Purdue Pharma L.P. 7/2013.
  20. Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses-a U.S. Epidemic. Morb Mortal Wkly Rep 2012; 61: 10-13.
  21. Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmor- tem database containing over 1000 cases. J Anal Toxicol 2003; 27: 57-67; discussion 67.
  22. Dhalla IA, Mamdani MM, Sivilotti ML, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181: 891-896. doi:10.1503/cmaj.090784.
  23. Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011; 8: 29-45. doi:10.1186/1477-7517-8-29.
  24. Butler SF, Budman SH, Licari A, et al. National addictions vigilance interven- tion and prevention program (NAVIPPRO): a real-time, product-specific public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142-1154. doi:10.1002/pds.1659.
  25. Katz N, Fernandez K, Chang A, et al. Internet-based survey of nonmedical pre- scription opioid use in the United States. Clin J Pain 2008; 24: 528-535. doi:10.1097/AJP.0b013e318167a087.
  26. Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of pre- scription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006; 20: 5-13.
  27. Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend 2013; 131: 100-105. doi:10.1016/j.drugalcdep.2012.12.006.
  28. Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol 2013; 27(9): 808-816. doi: 10.1177/0269881113493364.
  29. Perrino PJ, Colucci SV, Apseloff G, et al. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin ® tablets compared with original OxyContin ® tablets in healthy adults. Clin Drug Investig 2013; 33: 441-449. doi:10.1007/s40261-013-0085-x.
  30. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367: 187-189. doi:10.1056/NEJMc1204141.
  31. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administra- tion of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013; 14: 351-358. doi:10.1016/j.jpain.2012.08.008.
  32. Severtson SG, Bucher Bartelson B, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of OxyContin ® in 2010. J Pain 2013; 14: 1122-1130. doi:10.1016/j.jpain.2013.04.011.
  33. Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin expo- sures in the national poison data system after introduction of extended-release oxycodone with abuse deterrent characteristics. Pharmacoepidemiol Drug Saf 2013; 22: 1274-1282. doi:10.1002/pds.3522.
  34. Food and Drug and Administration. 2013b. FDA news release: FDA approves abuse-deterrent labeling for reformulated OxyContin, Available from: http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ UCM348252.htm [5 May 2013].
  35. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-2768.
  36. U.S. Food and Drug and Administration (FDA). Adverse event reporting system (AERS).Rockville, MD: FDA. Available from: http://www.fda.gov/cder/aers/de- fault.htm [28 January 2013].
  37. Greenland S. Dose response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-365.
  38. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology (3rd edn). Lippincott, Williams & Wilkins: Philadelphia, PA, 2008; 410.
  39. IMS health national prescription audit data purchased and received December 2013
  40. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administra- tion. J Gen Intern Med 2003; 18: 57-60.
  41. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveil- lance. Annu Rev Public Health 2010; 31: 419-437. doi:10.1146/annurev. publhealth.012809.103649.
  42. Rodriguez EM, Staffa A, Graham D. The role of databases in drug post- marketing surveillance. Pharmacoepidemiol Drug Saf 2001; 10: 407-410. doi:10.1002/pds.615.
  43. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan PM, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend [available ahead of print 27 February 2014] doi: 10.1016/j.drugalcdep.2014.02.018.
  44. Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEDA (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of post- marketing adverse events during the first year. J Opioid Manag 2012; 8: 115-125.
  45. Pearl J. Causality: Models, Reasoning and Inference. Cambridge University Press: Cambridge, United Kingdom, 2009; 5.
  46. FDA News Release. FDA introduces new safety measures for extended-release and long-acting opioid medications. July 9, 2012. Available at: http://www.fda.gov/ NewsEvents/ Newsroom/PressAnnouncements/ucm310870.htm [30 March 2013].
  47. U.S. Department of Justice Drug Enforcement Administration. Prescription drug monitoring programs. Available at: http://www.deadiversion.usdoj.gov/faq/ rx_monitor.htm [January 2011].
  48. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs im- pact state trends in opioid abuse/misuse? Pain Med 2012; 13: 434-442. doi:10.1111/j.1526-4637.2012.01327.x.
  49. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12: 747-754. doi:10.1111/j.1526-4637.2011.01062.x.
  50. Sauber-Schatz EK, Mack KA, Diekman ST, et al. Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hos- pitalizations, emergency department visits, and neonatal abstinence syndrome in Florida. Drug Alcohol Depend 2013; 133: 161-166. doi:10.1016/j. drugalcdep.2013.05.017.
  51. Albert S, Brason FW, Sanford CK, et al. Project Lazarus community-based over- dose prevention in rural North Carolina. Pain Med 2011; 12(Suppl 2): S77-S85. doi:10.1111/j.1526-4637.2011.01128.x.
  52. Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR Morb Mortal Wkl Rep 2012; 61: 101-105.
  53. National take-back initiative. US Department of Justice, Drug Enforcement Ad- ministration, Office of Diversion Control Web site. http://www.deadiversion. usdoj.gov/drug_disposal/takeback/ [11 February 2014].
  54. Gray JA. Prescription drug abuse and DEA-sanctioned drug take-back events: characteristics and outcomes in rural Appalachia. Arch Intern Med 2012; 172: 1186-1187. doi:10.1001/archinternmed.2012.2374.
  55. Silverman G. Heroin abuse: shooting up. Financial Times, February 9, 2014. Available at http://www.ft.com/intl/cms/s/0/d378673a-8fe3-11e3-aee9-00144feab7de. html?siteedition=intl.
  56. Office of National Control Policy. Epidemic: responding to America's prescrip- tion drug abuse crisis, 2011. http://www.whitehouse.gov/ondcp/prescription- drug-abuse [30 March 2013].